Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by technological advancements, increased investment, and supportive policies, indicating a promising future for the industry [3][6][9]. Market Performance - The Shanghai Composite Index recorded a 15-day consecutive rise, with the brain-computer interface concept continuing to surge, and the medical device ETF (159797) rising by 1.26% [1]. - The medical device ETF has seen a net inflow of over 27 million yuan in the past 20 days [1]. Investment and Financing - Strong Brain Technology has completed approximately 2 billion yuan in financing, becoming the second-largest financing project in the global BCI field [3]. - Neuralink, led by Elon Musk, plans to initiate large-scale production this year, with 12 severely paralyzed patients already implanted with their devices [3]. - Neuralink raised 650 million USD in a recent funding round, with plans to advance a "full-brain interface program" by 2028 [3]. Policy Developments - Sichuan Province has set clear pricing for BCI medical services, with the highest implantation fee at 6,583 yuan per procedure [4]. - The Chinese government is increasingly prioritizing brain science, with various policies being introduced to support the BCI industry [9]. Industry Growth Projections - The BCI market in China is projected to reach 3.2 billion yuan in 2024 and exceed 5.5 billion yuan by 2027 [11]. - Globally, the BCI market in the medical application sector is expected to reach 40 billion USD by 2030 and surpass 145 billion USD by 2040 [11]. Company Developments - Domestic companies are actively entering the BCI market, with over 200 firms reported, including Shanghai Ladder Medical and Beijing Brain Science Institute, which have made significant advancements in clinical trials [10]. - The medical device ETF (159797) covers a wide range of sectors, including high-value consumables and diagnostic equipment, with the top ten weighted stocks accounting for 45.04% of the fund [11].

Core Viewpoint - The company, Ruimaite (301367.SZ), clarified that it currently has no business cooperation with Qiangnao Technology, despite having investments in a related company, Deda Xing Drive Technology Co., Ltd. [1] Group 1: Company Holdings - Ruimaite directly holds 14.28% of the equity in Deda Xing Drive Technology Co., Ltd. [1] - A private equity fund established in collaboration with Beijing Fengyu Private Fund Management Co., Ltd. holds an additional 4.76% of Deda Xing Drive's equity. [1] Group 2: Client Relationships - Deda Xing Drive's core clients include Qiangnao Technology, indicating a potential indirect relationship through client connections. [1]

Core Viewpoint - The company, 瑞迈特, has invested in 深圳市德达兴驱动科技有限责任公司, which has strong clients including 强脑科技, but currently has no business cooperation with 强脑科技 [1] Group 1: Investment Details - 瑞迈特 directly holds 14.28% of the shares in 德达兴驱动 [1] - A private equity fund established in collaboration with 北京丰誉私募基金管理有限公司 holds an additional 4.76% of 德达兴驱动 [1] Group 2: Client Relationships - 德达兴驱动's core client includes 强脑科技 [1] - There is currently no business cooperation between 瑞迈特 and 强脑科技 [1]

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 摘要 ： 脑机接口（BCI）领域需要整合神经科学、生物医学工程、材料科学等多领域的科学仪器，本 文带你解锁脑机接口背后的科学仪器清单。 2 0 2 5年1 2月3 1日，马斯克通过社交媒体宣布，其脑机接口公司Ne u r a li n k将于 2 0 2 6 年 启 动 脑 机接口设备的"大规模生产" ， 同时 计划将植入物的电极通道 数 量 提 升 至 3 0 0 0 个 ， 并 帮 助 首 位"盲视"项目参与者恢复低分辨率视觉。 马斯克的言论直接点燃了资本市场的热情。2 0 2 6年A股开年首个交易日，脑机接口相关概念股 出现涨停潮，显示出市场对该技术商业化的强烈预期。 同样，在中国市场，2 0 2 6年1月7日， 脑机接口企业强脑科技宣布完成约2 0亿元新一轮融资， 创下该领域除Neur a link外的全球第二大单笔融资纪录。 资本重金押注，足以印证脑机接口 （ BCI ） 赛道的巨大潜力，要实现从实验室到产业化的跨 越，科学仪器作为核心技术载体的作用至关重要。 脑机接口 （ BCI ...

智通财经1月8日讯，沪指窄幅震荡，创业板指盘中跌超1%。沪深两市成交额2.8万亿，较上一个交易日缩量538亿，成交额连续4个交易日超2.5万亿。盘面 上，市场热点快速轮动，全市场超3700只个股上涨，其中111只个股涨停。从板块来看，商业航天概念集体爆发，二十余只成分股涨停，鲁信创投10天8板， 金风科技3连板。脑机接口概念延续强势，创新医疗、普利特、南京熊猫4连板。可控核聚变概念表现活跃，中国一重、国机重装、中国核建2连板。AI应用 概念走高，久其软件、宝信软件涨停。下跌方面，大金融、稀土永磁、有色金属等板块跌幅居前。其中证券方向集体下挫，华林证券跌停。截至收盘，沪指 跌0.07%，深成指跌0.51%，创业板指跌0.82%。 板块方面 商业航天再度全线爆发，鲁信创投、金风科技、泰胜风能、通宇通讯、航天电器、航天电子、航天科技、巨力索具等超二十股涨停。 行业角度来看，脑机接口行业已经形成了完整的产业链，涵盖上游(材料、芯片、电极等)、中游(信号采集感知处理等)、下游(医疗健康、生活消费、工业生 产等)等多个环节。 目前市场关注的重心还是以上游材料为主，当该题材持续发酵时，行业中下游或将获得更多资金关注。但考虑 ...

Core Viewpoint - The company, Zhongke Information (300678.SZ), has clarified that it has no collaboration with Qiangnao Technology and Nao Hu Technology, focusing instead on its partnership with the Suzhou Institute of Nano-Tech and Nano-Bionics of the Chinese Academy of Sciences to develop brain-like intelligence and smart medical applications [1] Group 1 - The company is collaborating with the Suzhou Institute of Nano-Tech and Nano-Bionics to establish a research center for brain-like intelligence and smart medical applications [1] - The partnership aims to conduct research on key technologies and innovative applications in various medical fields [1] - The focus areas include clinical auxiliary diagnosis and treatment, clinical scientific research, and regional health and wellness applications [1] Group 2 - The company plans to develop high-end intelligent medical and rehabilitation equipment, high-end smart wearable devices, and clinical research and auxiliary diagnosis systems and equipment [1] - These products are aimed at promoting domestic innovation in the medical technology sector [1]

Core Viewpoint - Qiangnao Technology has successfully completed a financing round of approximately 2 billion RMB, which will be used to accelerate the research and development of core brain-computer interface technologies, extreme engineering breakthroughs, and product scaling and mass production [1] Company Summary - The company aims to help 1 million physically disabled individuals regain daily life through the use of neuro-controlled prosthetics [1] - Qiangnao Technology also targets to improve the conditions of 10 million patients suffering from brain disorders such as autism, ADHD, Alzheimer's, and insomnia [1] - The company envisions a future where ordinary people can interact with the world directly through brain-computer interface devices, reshaping human-machine integration [1] Industry Summary - The "14th Five-Year Plan" has identified brain-computer interfaces as a key industry for future development, indicating a shift towards commercialization in this sector [1] - According to CITIC Securities research, brain-computer interfaces represent both medical and technological investments, with short-term applications focused on disease treatment and long-term potential in enhancing human capabilities, AI integration, and brain-controlled humanoid robots, which could open up a trillion-yuan market [1] - China is relatively advanced in brain-computer interface technology research globally, with the potential to cultivate leading companies in this field [1]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by technological advancements and increased investment, particularly in the A-share market, with related stocks showing strong performance [1][5]. Group 1: Market Performance - The medical device index ETF (159898) has seen a rise of over 1.94%, with approximately 37 million yuan in net inflow as of the report [1]. - Key stocks in the BCI sector include Kewei Medical, which surged over 19%, and Shuoshi Bio, which increased over 13%, among others [3]. Group 2: Industry Growth - The global BCI market has grown from $1.2 billion in 2019 to nearly $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13% [5]. - Projections indicate that the global BCI industry could reach $7.63 billion by 2029, with a CAGR of over 25% from 2024 to 2029 [5]. Group 3: Investment Opportunities - The BCI sector is positioned at a critical juncture with strong policy support, rapid technological iteration, and accelerated commercialization, making it a promising area for investment [8]. - The medical device index ETF (159898) tracks a broad range of medical device sectors, with leading companies like Mindray Medical and United Imaging Healthcare, providing a pure representation of the A-share medical device sector [8][9].

Core Insights - Strong Brain Technology, led by Han Bicheng, has secured approximately 2 billion yuan in funding, marking the largest financing in China's brain-computer interface sector [2] - This funding round positions Strong Brain Technology as the second largest globally in the brain-computer interface space, following Neuralink's 650 million USD Series E funding [2] Company Overview - Han Bicheng, the founder of Strong Brain Technology, is a 39-year-old from Mudanjiang, Heilongjiang, with a distinguished academic background, including a bachelor's degree in mechanical engineering from the Korea Advanced Institute of Science and Technology and a PhD from Harvard University [3][4] - The company was established in 2015, and Han chose to return to China to start the business before completing his PhD [5] Technology and Product Development - Strong Brain Technology focuses on non-invasive brain-computer interface technology, which is considered a "non-mainstream" approach compared to the invasive methods predominantly supported by investors [6][8] - The company has developed a "super sensor" capable of detecting neural signals, achieving over 95% accuracy in signal recognition compared to medical-grade EEG devices [8] - Products include smart bionic limbs and brain-computer intelligent sleep devices, with a production milestone of 100,000 high-precision brain-computer interface products reached in 2022 [8] Market Position and Future Goals - The market price for the smart bionic hand is approximately 100,000 yuan, significantly lower than similar foreign products, and allows for immediate use after installation [10] - Strong Brain Technology aims to assist over 6,000 disabled individuals in regaining mobility by 2025, with a long-term vision of helping 1 million individuals with limb disabilities and 10 million patients with Alzheimer's, autism, and insomnia over the next 5 to 10 years [10][12] - The company's valuation reached 9 billion yuan in the 2025 Hurun Global Unicorn List, reflecting its growth and potential in the industry [12]

Core Insights - The brain-computer interface (BCI) concept continues to gain momentum, with related stocks experiencing significant increases, particularly in the medical device sector [1][2]. Group 1: Market Performance - The medical device index ETF (159898) has seen a rise of over 1.94%, with approximately 37 million yuan in net inflow as of the latest report [1]. - Key stocks such as Kewei Medical surged over 19%, while others like Shuoshi Bio and Lepu Medical increased by over 13% and 6% respectively [1]. Group 2: ETF and Index Details - The medical device index ETF (159898) tracks the CSI All Share Medical Device Index, with a BCI concept weight of about 24% [2][3]. - The ETF's latest scale is 536 million yuan, and it has outperformed its peers since 2025 [2]. Group 3: Industry Growth and Projections - The global BCI market size grew from 1.2 billion USD in 2019 to nearly 2 billion USD in 2023, with a compound annual growth rate (CAGR) exceeding 13% [4]. - Projections indicate that the global BCI industry could reach 7.63 billion USD by 2029, with a CAGR of over 25% from 2024 to 2029 [4]. Group 4: Investment Opportunities - The BCI sector is currently experiencing a high-growth phase driven by technological breakthroughs, policy support, and ecosystem collaboration [7]. - The medical field is identified as the most mature and largest segment for BCI commercialization, making it a key area for investment [7].